Elpiscience Starts US Trial of Novel CD39 Immunotherapy
January 21, 2022 at 05:14 AM EST
Shanghai Elpiscience Bio has started a US Phase I trial of its novel anti-CD39 monoclonal antibody in patients with advanced solid tumors. CD39 is a key enzyme regulating the production of adenosine, a critical immune suppressor. The candidate, ES002, has shown single-agent anti-tumor activity in pre-clinical studies. The Phase I clinical trial will evaluate the safety, tolerability and preliminary clinical activity of ES002. An immuno-oncology company, Elpiscience now has four molecules in clinical trials. More details.... Share this with colleagues: // //
